Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lu-Feng Cheng has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Yong-Zheng Zhang

    Department of Pharmacology, School of Pharmacy, Xinjiang Medical University, Ürümqi, China

    4 shared publications
  • Hui-Lan Zhang

    Department of Pharmacy

    3 shared publications
  • Jing Yu

    Department of Neurology, Xinjiang Hospital of Beijing Children’s Hospital, Children’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China

    3 shared publications
  • Lu-Hai Yu

    Department of Pharmacy, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China

    3 shared publications
  • Ting Zhao

    Department of Pharmacology, School of Pharmacy, Xinjiang Medical University, Xinjiang Key Laboratory of Biopharmaceuticals and Medical Devices

    3 shared publications
  • Yang Wu

    Department of Pharmacology, School of Pharmacy, Xinjiang Medical University, Ürümqi, China

    3 shared publications

Latest Publications

  • Open Access

    CD180-Associated B-Cell Alterations in Type 1 Diabetes and the In Vitro Effects of Chlorogenic Acid: An Integrated Transcriptomic and Experimental Study

    by Zihang Wang, Arzu Mijit, Rong Han, Mengjia Li, Yang Wu, Lufeng Cheng

    Type 1 diabetes mellitus (T1DM) is an autoimmune disease involving progressive loss of pancreatic β-cells. Although B cells have been implicated in T1DM progression, the molecular characteristics associated with disease-related B-cell states remain unclear. Here, we investigated B-cell-associated molecular alterations in T1DM and explored the potential immunomodulatory effects of a natural compound. Public T1DM transcriptomic datasets were analyzed using differential expression analysis, WGCNA, and machine-learning approaches. Single-cell RNA sequencing was used to characterize Cd180 expression across B-cell states. Molecular docking and molecular dynamics simulations were used to explore potential interactions between CD180 and candidate compounds, and an exploratory DARTS assay was performed to assess CGA-associated changes in CD180 proteolytic susceptibility. CD180 expression was examined in pancreatic tissues from vehicle- and MSA-2-treated NOD mice. The effects of chlorogenic acid (CGA) were evaluated in vitro by exposing B cells to CGA during inflammatory stimulation, followed by washing and co-culture with MIN6 cells in CGA-free medium. Integrated transcriptomic analysis identified four T1DM-associated genes (CD180, KCNJ2, STEAP4, and ZXDA), among which CD180 showed the strongest association with B-cell-related immune alterations. Single-cell analysis showed increased Cd180 expression in inflammatory B-cell states together with enrichment of antigen-presentation-related programs. An exploratory DARTS experiment with matched loading-control data suggested altered CD180 proteolytic susceptibility following CGA exposure, although independent reproducibility remains to be established. In vitro, CGA exposure during inflammatory stimulation was associated with reduced CD180 expression in B cells and improved MIN6 cell viability and insulin-secretory responses during subsequent co-culture in CGA-free medium. CD180 is associated with inflammatory B-cell alterations in T1DM and may represent a candidate molecular feature of B-cell dysregulation. CGA treatment was associated with changes in CD180 expression in activated B cells and improved β-cell functional outcomes in vitro. These findings support further investigation of the relationship between CGA and CD180; however, whether the effects of CGA are specifically mediated through CD180 requires further experimental validation.

  • Individualized perampanel response and efficacy in patients with refractory epilepsy: the need for ATP-binding cassette B1 genotyping and therapeutic drug monitoring to work in tandem

    by Ting Zhao, Hong-Jian Li, Hui-Lan Zhang, Jing Yu, Yan Sun, Lu-Hai Yu, Lu-Feng Cheng

    Objective: This study analyzed the correlation and differences between the gene polymorphisms of ATP-binding cassette B1 ( ABCB1 ), which encode the efflux drug transporter P-glycoprotein, and the efficacy and plasma concentration of perampanel (PER) in patients with refractory epilepsy. Methods: Plasma samples were collected from 115 patients with epilepsy who received PER treatment for at least 21 days. The ABCB1 genotypes were detected using first-generation Sanger sequencing, and the PER plasma concentration was measured using ultra-high performance liquid chromatography-mass spectrometry. Results: The overall efficacy of PER in treating patients with refractory epilepsy was observed in 64.3% of patients. The ABCB1 rs2032582 gene polymorphisms were significantly associated with the therapeutic efficacy of PER in refractory epilepsy. When compared with patients with the wild-type homozygous genotype, the plasma concentrations of PER were significantly higher for patients with the P-glycoprotein-encoding ABCB1 rs2032582 and ABCB1 rs1045642 mutant genotypes ( P < 0.05). When the plasma concentration of PER exceeded 305 ng/ml, patients more effectively responded to PER treatment (area under the curve: 0.614, P < 0.05). Conclusion: ABCB1 gene polymorphisms are important predictors of effective with PER treatment and serve as factors that affect the achievement of therapeutic plasma concentrations of PER, and they have contrasting effects.

  • KCNA3 Gene Polymorphism Affects the Efficacy and Plasma Concentration of Perampanel in Patients With Refractory Epilepsy

    by Ting Zhao, Hong-Jian Li, Hui-Lan Zhang, Jing Yu, Yan Sun, Lu-Hai Yu, Lu-Feng Cheng

    Background: Perampanel (PER) is the only third-generation anti-seizure medication targeting AMPA receptors, but its efficacy varies between patients. Whether KCNA3 polymorphisms influence PER response in drug-resistant epilepsy remains unknown. This study aims to evaluate the impact of KCNA3 rs2821557 polymorphisms on PER efficacy and plasma concentrations in patients with refractory epilepsy. Methods: Blood samples were collected from 119 patients who received PER for at least 3 weeks, in accordance with inclusion and exclusion criteria. KCNA3 rs2821557 genotypes were identified using first-generation Sanger sequencing, and plasma PER concentrations were quantified by ultra-high-performance liquid chromatography to assess associations between the KCNA3 rs2821557 gene polymorphism, PER efficacy, and plasma drug concentrations. Results: The therapeutic efficacy of PER in managing patients with refractory epilepsy was 65.55% (78/119). The proportion of patients with the KCNA3 rs2821557 TT genotype was significantly greater in the effective group than the ineffective group. Plasma PER concentrations in patients with CT or TT genotypes were significantly lower than in those with the CC genotype, a pattern also observed in patients aged 4–14 years, female patients, patients with a body mass index ranging from 18.5 to 24.0 kg/m, and patients with disease duration exceeding 1 year. Conclusions: The KCNA3 rs2821557 polymorphism is an important predictor of the therapeutic efficacy of PER in controlling epileptic seizures and a determinant of the attainment of therapeutic plasma PER concentrations.

  • Associations of SLCO gene polymorphisms with perampanel response and plasma concentrations in patients: a longitudinal retrospective real-world study in refractory epilepsy

    by Ting Zhao, Hong-Jian Li, Hui-Lan Zhang, Jing Yu, Yan Sun, Lu-Hai Yu, Lu-Feng Cheng

    1. The primary approach for epilepsy management involves the prolonged administration of anti-seizure medications (ASMs) [1]. However, more than 30% of patients are unable to control their seizures...

  • Open Access

    Single-Cell RNA Sequencing Reveals Lactylation Modifications in Neuroblastoma and the Construction of a Prognostic Model

    by Wuhe Jike, Ke Tian, Junming Zhu, Kutluk Kasim, Xiao Zhi, Lufeng Cheng, Xuejun Xiao

    Lactylation, a recently identified post-translational modification, has been associated with multiple cancer types, including neuroblastoma (NB). The present study aimed to investigate the prognostic significance of lactylation-related genes and to develop a prognostic model to enhance patient risk stratification and guide targeted therapy for NB. In the present bioinformatics study, single-cell RNA sequencing data (GSE137804) were analyzed to quantify lactylation activity in NB cells using the AddModuleScore algorithm based on 371 lactylation-related genes. A total of 142 differentially expressed lactylation-related genes (DELGs) were identified between high- and low-lactylation tumor cells, and these genes were mainly enriched in cell cycle-related pathways. A 14-gene lactylation-related prognostic model was then constructed using the identified DELGs in a training cohort (GSE49710, n = 349) via Cox and LASSO regression, and validated in internal (GSE49710, n = 149) and external (E-MTAB-8248, n = 223) cohorts. The model effectively stratified patients into high- and low-risk groups with significantly different overall survival (OS) outcomes, and its robust predictive performance was confirmed across both validation cohorts. The present study reveals the significant prognostic role of lactylation in NB, and the 14-gene model serves as a novel molecular tool for risk stratification and provides a reference for developing targeted therapeutic strategies for NB.

  • Open Access

    Molecular Mechanism of POSTN Mediating M2 Polarization of Kupffer Cells to Promote Hepatic Fibrosis

    by Meng-Dan Wang, Shuo-Ying Yuan, Arzu Mijit, Wen Zhang, Yang Wu, Lu-Feng Cheng

    Background/Objectives: Liver diseases cause more than 2 million annual deaths globally, accounting for 4% of the total global mortality rate. Hepatic fibrosis (HF) acts as an indispensable pathological mediator in the progressive deterioration of chronic liver diseases. Thus, the identification of effective anti-fibrotic targets and rational development of corresponding therapeutic agents are expected to deliver profound clinical value for patients suffering from chronic liver disorders. Methods: An in vivo HF model was established to detect Kupffer cell (KC) polarization and periostin (POSTN) protein expression. In vitro, the CCK-8 (Cell Counting Kit-8) assay was applied to evaluate the regulatory effects of Postn-knockdown macrophages on LX-2 cell activity. Conditional knockout mice with Postn were constructed in vivo, and liver tissue samples were used for single-cell sequencing. Functional enrichment and cell differentiation prediction analyses were performed. CellChat was further utilized to characterize alterations in intercellular communication between Postn-deficient KCs and adjacent liver cells. Finally, POSTN-targeted inhibitors were screened and validated via virtual drug screening and experiments. Results: In the HF model, the M2 polarization of KCs was associated with the upregulated expression of POSTN. In contrast, in vitro Postn knockdown correlated with significantly suppressed LX-2 cell activation. Single-cell profiling suggests that Postn deficiency in Kupffer cells is linked to remodeling of the hepatic microenvironment. In drug repurposing, Rhodiosin exhibited binding affinity to POSTN and was observed to inhibit macrophage M2 polarization. Conclusions: POSTN may contribute to KC M2 polarization and be associated with remodeling of the intercellular interaction network among liver cells. Rhodiosin, as a POSTN-binding compound, shows potential for anti-hepatic fibrotic effects.

  • Salvianolic acid C attenuates liver fibrosis and inhibites hepatic stellate cell activation by targeting FAP/TβRI/SMAD axis

    by Tao Sun, Xue Zheng, Liang Li, Jin Chu, Qiang Guo, Ning Yang, Xue Zhang, Xiaotong Li, Bowen Shi, Hongbin Zhang, et al.


  • Open Access

    Exploring Bioinformatics Tools to Analyze the Role of CDC6 in the Progression of Polycystic Ovary Syndrome to Endometrial Cancer by Promoting Immune Infiltration

    by Yuhang Song, Jing Zhang, Yao Li, Lufeng Cheng, Hua Song, Yuhang Zhang, Guoqing Du, Sunyue Yu, Yizhou Zou, Qi Xu

    Cell division cycle 6 (CDC6) is essential for the initiation of DNA replication in eukaryotic cells and contributes to the development of various human tumors. Polycystic ovarian syndrome (PCOS) is a reproductive endocrine disease in women of childbearing age, with a significant risk of endometrial cancer (EC). However, the role of CDC6 in the progression of PCOS to EC is unclear. Therefore, we examined CDC6 expression in patients with PCOS and EC. We evaluated the relationship between CDC6 expression and its prognostic value, potential biological functions, and immune infiltrates in patients with EC. In vitro analyses were performed to investigate the effects of CDC6 knockdown on EC proliferation, migration, invasion, and apoptosis. CDC6 expression was significantly upregulated in patients with PCOS and EC. Moreover, this protein caused EC by promoting the aberrant infiltration of macrophages into the immune microenvironment in patients with PCOS. A functional enrichment analysis revealed that CDC6 exerted its pro-cancer and pro-immune cell infiltration functions via the PI3K-AKT pathway. Moreover, it promoted EC proliferation, migration, and invasion but inhibited apoptosis. This protein significantly reduced EC survival when mutated. These findings demonstrate that CDC6 regulates the progression of PCOS to EC and promotes immune infiltration.


  • Open Access

    Identification of macrophage driver genes in fibrosis caused by different heart diseases based on omics integration

    by Yong-Zheng Zhang, Yang Wu, Meng-Jia Li, Aerzu Mijiti, Lu-Feng Cheng

    Myocardial fibrosis, a hallmark of heart disease, is closely associated with macrophages, yet the genetic pathophysiology remains incompletely understood. In this study, we utilized integrated single-cell transcriptomics and bulk RNA-seq analysis to investigate the relationship between macrophages and myocardial fibrosis across omics integration. We examined and curated existing single-cell data from dilated cardiomyopathy (DCM), ischemic cardiomyopathy (ICM), myocardial infarction (MI), and heart failure (HF), and analyzed the integrated data using cell communication, transcription factor identification, high dimensional weighted gene co-expression network analysis (hdWGCNA), and functional enrichment to elucidate the drivers of macrophage polarization and the macrophage-to-myofibroblast transition (MMT). Additionally, we assessed the accuracy of single-cell data from the perspective of driving factors, cell typing, anti-fibrosis performance of left ventricular assist device (LVAD). Candidate drugs were screened using L1000FWD. All four heart diseases exhibit myocardial fibrosis, with only MI showing an increase in macrophage proportions. Macrophages participate in myocardial fibrosis through various fibrogenic molecules, especially evident in DCM and MI. Abnormal RNA metabolism and dysregulated transcription are significant drivers of macrophage-mediated fibrosis. Furthermore, profibrotic macrophages exhibit M1 polarization and increased MMT. In HF patients, those responding to LVAD therapy showed a significant decrease in driver gene expression, M1 polarization, and MMT. Drug repurposing identified cinobufagin as a potential therapeutic agent. Using integrated single-cell transcriptomics, we identified the drivers of macrophage-mediated myocardial fibrosis in four heart diseases and confirmed the therapeutic effect of LVAD on improving HF with single-cell accuracy, providing novel insights into the diagnosis and treatment of myocardial fibrosis.